INTERNATIONAL WOMEN IN MULTIPLE SCLEROSIS

This recording from Thursday, 27 November 2025 features leading international experts who discuss the importance of accurate assays for diagnosing AQP4-NMOSD and MOGAD, explore regional assay availability, and share innovative approaches for sample testing and disease monitoring.

Agenda:

• Welcome and introduction – The importance of having accurate assays for the diagnosis of AQP4-NMOSD and MOGAD - Sara Samadzadeh (Germany/Denmark)

• Current assays available for testing (assay availability survey) - Patrick Waters (UK)

• Q&A – Regional perspectives on assay availability- Adriana Casallas Vanegas (Colombia/Spain) & Sanja Glucevic (Montenegro)

• Sample types and testing approaches: CSF vs. serum for AQP4-NMOSD and MOGAD - Sara Mariotto (Italy) - Other approaches and experiences (Rapid IDOT)

• Other approaches and experiences (Rapid IDOT) - Rui Li (China) 

• Limited availability of Live CBA for AQP4-IgG testing in LATAM countries - Vinícius Boldrini (Brazil)

• Closing and wrap-up

The iWiMS Clinical Research Group convened in October 2025 to discuss ongoing and emerging clinical research initiatives.

Please note, these videos are intended for a medical and scientific audience for educational purposes. Please acknowledge the speaker if you reference their work.

For the November 2024 Global Epidemiology Study Group, iWiMS featured Mitra Barzine who spoke on "Scrutinizing NMOSD and MOGAD: Genetic Insights From French Patient cohort", as well as Chloe Pierret, who spoke on "Cancer Risk Among Patients with Multiple Sclerosis."

Please note, these videos are intended for a medical and scientific audience for educational purposes. Please acknowledge the speaker if you reference their work.

For the August 2024 Global Epidemiology Conference, iWiMS featured Dr. Claudia Pestchanker, Hospital Central Dr. Ramón Carrillo, Argentina and Dr. Prashanth Rajarajan, Massachusetts General Brigham, United States.

Dr. Pestchanker spoke about MOGAD and the Latin American region and its limitations in clincial practice. Dr. Rajarajan discussed neurologic outcomes in people with MS who are treated with immune checkpoint inhibitors for oncologic indications.

Please note, these videos are intended for a medical and scientific audience for educational purposes. Please acknowledge the speaker if you reference their work.

For the February 2024 Global Epidemiology Conference, iWiMS featured Dr. Zuhal Abasiyanik who spoke on the use of psychometric properties of patient-reported outcome measures to assess dual-task difficulties in daily life, as well as Dr. Gloria Dalla Costa, who spoke on a wearable device perspective on the standard definitions of disability progression in multiple sclerosis.

Please note, these videos are intended for a medical and scientific audience for educational purposes. Please acknowledge the speaker if you reference their work.